Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Two Dosages of QIVIGY in CIDP
NCT06752356Phase 3Recruiting
- Sponsor
- Kedrion Biopharma
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of immune globulin intravenous (human) in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Kedrion Biopharma. Started Oct 2026; status: recruiting.
02
Drugs
immune globulin intravenous (human)
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06752356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752356.